EBIT at other companies
Other financials
Where this comes from
Calculated from Supernus Pharmaceuticals’s reported figures.
Plus components not separately reported this period.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's EBIT?
- Supernus Pharmaceuticals (SUPN) reported EBIT of -$8.33M in Q1 2026.
- How has Supernus Pharmaceuticals's EBIT changed year-over-year?
- Supernus Pharmaceuticals's EBIT increased by 18.8% year-over-year, from -$10.26M to -$8.33M.
- What is the long-term trend for Supernus Pharmaceuticals's EBIT?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's EBIT has grown at a -7.8% compound annual growth rate (CAGR), from $86.03M to -$62.28M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.